To assess whether phosphorylation sites on known members of PI3K, MEK, and JAK pathways would correlate with the responses of our AML cell line panel to the kinase inhibitors tested, we also specifically considered phosphorylation sites that, based on the literature, are known to be downstream of these kinases. The gene discussed is MAP2K7; the disease is acute myeloid leukemia.